drugset / Trial / NCT03639480

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

NCT03639480

Phase 3 Unknown 180 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia

Timeline

Start
2017-10-13
Primary completion
2018-10
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Comparator Atorvastatin Small molecule 40 mg
Comparator Valsartan Small molecule 160 mg